RxSight, Inc. (RXST) Financial Statements
RxSight, Inc. (RXST) reported trailing twelve-month revenue of $127.6M (down 3.9% year on year) and net income of -$46.9M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$27.2M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
RXSTRxSight, Inc.Follow RXST — free
—
Price chart with a free account
- Market cap
- 208.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 3 Nov, in 10 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Revenue | 22.6 | 49.0 | 89.1 | 139.9 | 134.5 | 127.6 | |
| Gross profit | 4.5 | 21.3 | 53.8 | 98.9 | 103.0 | — | |
| Research & development | 24.5 | 26.0 | 29.1 | 34.4 | 38.5 | 36.7 | |
| Operating income | -52.8 | -63.3 | -50.1 | -36.9 | -48.2 | -55.1 | |
| Pre-tax income | -48.7 | -66.7 | -48.6 | -27.4 | -38.9 | -46.8 | |
| Income tax | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | |
| Net income | -48.7 | -66.8 | -48.6 | -27.5 | -38.9 | -46.9 | |
| Diluted EPS ($) | -3.57 | -2.41 | -1.41 | -0.71 | -0.95 | -1.13 | |
| Diluted shares (mn) | 13.6 | 27.7 | 34.5 | 38.9 | 40.9 | — |
USD millions · SEC XBRL
RxSight, Inc. — questions
- What is RxSight, Inc.'s revenue?
- $127.6M over the twelve months to 2026-06-30, down 3.9% year on year, from its 10-Q and 10-K filings.
- What is RxSight, Inc.'s net income?
- -$46.9M over the twelve months to 2026-06-30.
- What is RxSight, Inc.'s free cash flow?
- -$27.2M over the twelve months to 2026-06-30.
- What are RxSight, Inc.'s diluted earnings per share?
- $-1.13 over the twelve months to 2026-06-30.
Every figure on this page comes from RxSight, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.